nach oben

Clinical and Experimental Medicine

Erschienen in:

27.12.2016 | Original Article

Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry

verfasst von: Natália Aydos Marcondes, Flavo Beno Fernandes, Ana Paula Alegretti, Gustavo Adolpho Moreira Faulhaber

Erschienen in: Clinical and Experimental Medicine | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Bruton’s tyrosine kinase (BTK) is a cytoplasmatic protein that is part of the B-cell antigen receptor signaling pathway. Our aim was to evaluate the expression of BTK in B-cell neoplasms and compare it to normal B-cell lymphocytes. After surface staining with CD19 and CD45, flow cytometry staining for intracellular BTK was performed in leukemic or mature B-cells from bone marrow or peripheral blood samples. No differences in BTK expression were identified between groups, or in comparison to control samples, there was no association between BTK expression and the clinical variables evaluated. BTK expression in B-cell neoplasms was similar to that of normal B-cell lymphocytes.

Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58–73. doi:10.1111/j.1600-065X.2008.00741.x.CrossRefPubMed

Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(12):2362–70. doi:10.3109/10428194.2012.695781.CrossRefPubMedPubMedCentral

Brunner C, Muller B, Wirth T. Bruton’s tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol. 2005;20(3):945–55.PubMed

Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012;7(1):26–33. doi:10.1007/s11899-011-0104-z.CrossRefPubMed

Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematol Am Soc Hematol Educ Progr. 2013;2013:553–60. doi:10.1182/asheducation-2013.1.553.

Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71–81. doi:10.1016/j.semcancer.2013.08.011.CrossRefPubMed

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–80. doi:10.1073/pnas.1004594107.CrossRefPubMedPubMedCentral

Roskoski R Jr. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacol Res. 2016;113(Pt A):395–408. doi:10.1016/j.phrs.2016.09.011.CrossRefPubMed

Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.

10.

Davis BH, Dasgupta A, Kussick S, Han JY, Estrellado A. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS—part II—preanalytical issues. Cytom B Clin Cytom. 2013;84(5):286–90. doi:10.1002/cyto.b.21105.CrossRef

11.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287–96. doi:10.1182/blood-2011-01-328484.CrossRefPubMedPubMedCentral

12.

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649–57. doi:10.1038/leu.2013.358.CrossRefPubMed

13.

Fernandez-Vega I, Quiros LM, Santos-Juanes J, Pane-Foix M, Marafioti T. Bruton’s tyrosine kinase (BTK) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Arch. 2015;466(2):229–35. doi:10.1007/s00428-014-1698-z.CrossRefPubMed

14.

Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271–7. doi:10.1016/j.leukres.2013.07.028.CrossRefPubMed

15.

Futatani T, Miyawaki T, Tsukada S, Hashimoto S, Kunikata T, Arai S, et al. Deficient expression of Bruton’s tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood. 1998;91(2):595–602.PubMed

16.

Kaneko H, Kawamoto N, Asano T, Mabuchi Y, Horikoshi H, Teramoto T, et al. Leaky phenotype of X-linked agammaglobulinemia in a Japanese family. Clin Exp Immunol. 2005;140(3):520–3. doi:10.1111/j.1365-2249.2005.02784.x.CrossRefPubMedPubMedCentral

17.

Teocchi MA, Domingues Ramalho V, Abramczuk BM, D’Souza-Li L, Santos Vilela MM. BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients. Immun Inflamm Dis. 2015;3(3):171–81. doi:10.1002/iid3.57.CrossRefPubMedPubMedCentral

18.

Nisitani S, Satterthwaite AB, Akashi K, Weissman IL, Witte ON, Wahl MI. Posttranscriptional regulation of Bruton’s tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA. 2000;97(6):2737–42. doi:10.1073/pnas.050583597.CrossRefPubMedPubMedCentral

19.

Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71–83.PubMedPubMedCentral

20.

Wang SP, Iwata S, Nakayamada S, Niiro H, Jabbarzadeh-Tabrizi S, Kondo M, et al. Amplification of IL-21 signalling pathway through Bruton’s tyrosine kinase in human B cell activation. Rheumatology (Oxford). 2015;54(8):1488–97. doi:10.1093/rheumatology/keu532.CrossRef

Titel: Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry
verfasst von: Natália Aydos Marcondes
Flavo Beno Fernandes
Ana Paula Alegretti
Gustavo Adolpho Moreira Faulhaber
Publikationsdatum: 27.12.2016
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 4/2017
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-016-0447-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Cycling CD34 expression in subpopulations of head and neck squamous cell carcinoma cell lines is involved in radioresistance and change in cytokeratin expression profile

Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness

Spatial distribution of mast cells around vessels and glands in human gastric carcinoma

Upregulation of ROCK2 in gastric cancer cell promotes tumor cell proliferation, metastasis and invasion

Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis

Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin